Roche buys into petrelintide in a bet that amylin is the next act
Roche agreed to co-develop and co-commercialise Zealand Pharma's long-acting amylin analogue, one of the largest partnership payments yet for an obesity peptide still in mid-stage trials.
What's new
Roche and Zealand Pharma will jointly develop petrelintide, alone and in combination with Roche's own incretin candidate, with $1.65bn paid upfront.
Why it matters
It is a large wager that amylin drugs can deliver meaningful weight loss with better tolerability than GLP-1 alone.
What's next
Phase 2 readouts for petrelintide as a single agent will show whether the bet holds.
Swiss drugmaker Roche agreed to pay Zealand Pharma $1.65 billion upfront to co-develop petrelintide, a once-weekly amylin analogue in clinical trials for obesity. Additional milestone payments could bring the total to around $5.3 billion.
What petrelintide is
Amylin is a 37-amino-acid hormone released by the pancreas together with insulin. It signals fullness and slows how fast the stomach empties. Natural amylin clumps easily and lasts minutes, so drug versions are engineered to stay soluble and stay in the body for days.
The thesis
GLP-1 drugs work well but cause nausea in many people, and some patients lose muscle along with fat. Amylin-based drugs are being studied in the hope of:
- Similar or complementary weight loss.
- A gentler side-effect profile.
- Better combination potential with GLP-1 or GIP based peptides.
None of these points is proven yet. Early data are small and short.
Why big pharma pays early
Several large companies without a leading obesity drug have turned to partnerships rather than starting from scratch. Buying in at phase 2 is expensive, but waiting for phase 3 data usually costs more.
| Company | Amylin approach |
|---|---|
| Novo Nordisk | Cagrilintide, alone and in CagriSema |
| Zealand / Roche | Petrelintide |
| Others | Several oral and injectable programmes in early trials |
